Antioxidant therapy in ALS

Amyotrophic Lateral Sclerosis

Volumn 1, Issue SUPPL. 4, 2000, Pages 5-15

  Pioro, Erik P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT;

AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; METABOLISM; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANTS; HUMANS;

EID: 0347303317     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820050515656     Document Type: Article

References (66)

1. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or .ction? Ann Neurol 1992; 32: S10-S15.
2. Halliwell B, Aruoma OI. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 1991; 281 (1-2): 9-19.
3. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186: 1-85. (Pubitemid 20279941)
4. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants, and human disease: Where are we now? J Lab Clin Med 1992; 119: 589-620.
5. Patterson D, Warner HR, Fox LM, Rahmani Z. Superoxide dismutase, oxygen radical metabolism, and amyotrophic lateral sclerosis. Molec Genet Med 1994; 4: 79-119.
6. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992; 32: S2-S9.
7. Fridovich I. The biology of oxygen radicals. Science 1978; 209: 875-887.
8. Rosen DR, Siddique T, Patterson D. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62. (Pubitemid 23087289)
9. Deng H-X, Hentati A, Tainer JA. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993; 261: 1047-1051. (Pubitemid 23300865)
10. Robberecht W, Sapp P, Viaene MK. Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1994; 62: 384-387.
11. Bowling AC, Schulz JB, Brown RH, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61: 2322-2325. (Pubitemid 23354097)
12. Lipton SA, Choi Y-B, Pan Z-H, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364(6438): 626-632. (Pubitemid 23274719)
13. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991; 88: 6368-6371. (Pubitemid 21914947)
14. Borchelt DR, Lee MK, Slunt HS. Superoxide dismutase 1 with mutations linked to familial amyotrophic sclerosis possesses signi.cant activity. Proc Natl Acad Sci USA 1994; 91: 8292-8296. (Pubitemid 24253933)
15. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997; 152 (Suppl 1): S67-S73. (Pubitemid 27505293)
16. Reider CR, Paulson GW. Lou Gehrig and amyotrophic lateral sclerosis: Is vitamin E to be revisited? Arch Neurol 1997; 54: 527-528. (Pubitemid 27204237)
17. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-7922. (Pubitemid 23260825)
18. Terro F, Lesort M, Viader F, Ludolph A, Hugon J. Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. NeuroReport 1996; 7: 1970-1972. (Pubitemid 26348205)
19. Hall ED, Andrus PK, Oostveen JA, Fleck TJ, Gurney ME. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 1998; 53: 66-77. (Pubitemid 28308982)
20. Kruman II, Pedersen WA, Springer JE, Mattson MP. ALSlinked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving oxidative stress and perturbed calcium homeostasis. Exp Neurol 1999; 160: 28-39.
21. Ghadge GD, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci 1997; 17: 8756-8766. (Pubitemid 27481742)
22. Gurney ME, Cuttin FD, Zhai P, et al. Bene.t of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157. (Pubitemid 26071564)
23. Wechsler IS. Recovery in amyotrophic lateral sclerosis. Neurology 1940; 114: 948-950.
24. Wechsler IS. The treatment of amyotrophic lateral sclerosis with vitamin E (tocopherols). Am J Med Sci 1940; 200: 765-778.
25. Norris FH, Denys EH. Nutritional supplements in amyotrophic lateral sclerosis. Adv Exp Med Biol 1987; 209: 183-189.
26. Doyle AM, Merritt HH. Vitamin therapy of diseases of the neuromuscular apparatus. Arch Neurol Psych 1941; 45: 672-679.
27. Bieri JG, Corash L, Hubbard VS. Medical uses of vitamin E. N Engl J Med 1983; 308: 1063-1071. (Pubitemid 13124895)
28. Dorman JD, Engel WK, Fried DM. Therapeutic trial in amyotrophic lateral sclerosis. Lack of bene.t with pancreatic extract and DL-alpha tocopherol in 12 patients. J Am Med Assoc 1969; 209: 257-258.
29. Spector R, Eells J. Deoxynucleotide and vitamin transport into the central nervous system. Fed Proc 1984; 43: 196-200. (Pubitemid 14185137)
30. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate, and free radicals: combinations to avoid. Radiat Res 1996; 145: 532-541. (Pubitemid 26127160)
31. Nagano S, Ogawa Y, Yangihara T, Sakoda S. Bene.t of acombined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 1999; 265: 159-162. (Pubitemid 29207390)
32. Ikeda K, Kinoshita M, Iwasaki Y. Lecithinized superoxide dismutase retards wobbler mouse motor neuron disease. Neuromusc Disord 1995; 5: 383-390.
33. Smith RA, Balis FM, Ott KH, Elsberry DD, Sherman MR, Saifer MGP. Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary observations in familial ALS. J Neurol Sci 1995; 129 (Suppl): 13-18.
34. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-597. (Pubitemid 19147809)
35. Meister A. Selective modi.cation of glutathione metabolism. Science 1983; 220: 472-477. (Pubitemid 13114104)
36. Henderson JT, Javaheri M, Kopko S, Roder JC. Reduction of lower motor neuron degeneration in wobbler mice by Nacetyl-L-cysteine. J Neurosci 1996; 16: 7574-7582. (Pubitemid 26389697)
37. Jaarsma D, Guchelaar H-J, Haasdijk E, de Jong JM, Holstege JC. The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 1998; 44: 293. (Pubitemid 28374126)
38. Rothstein JD. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA 1994; 91: 4155-4159. (Pubitemid 24143391)
39. Louwerse ES, Weverling GJ, Bossuyt PM, Meyes FE, deJong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995; 52: 559-564.
40. Braughler JM, Burton PS, Chase RL, et al. Novel membrane localized iron chelators as inhibitors of iron-dependent lipid peroxidation. Biochem Pharmacol 1988; 37: 3853-3860.
41. Gonzalez Deniselle MC, Gonzalez SL, Lima AE, Wilkin G, DeNicola A.F. The 21-aminosteroid U-74389F attenuates hyperexpression of GAP-43 and NADPH-diaphorase in the spinal cord of wobbler mouse, a model for amyotrophic lateral sclerosis. Neurochem Res 1999; 24: 1-8. (Pubitemid 29067769)
42. Reinholz MM, Merkle CM, Poduslo JF. Therapeutic bene.ts of putrescine-modi.ed catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol 1999; 159: 204-216. (Pubitemid 29444916)
43. Behl C. Vitamin E and other antioxidants in neuroprotection. Internat J Vit Nutrition Res 1999; 69: 213-219. (Pubitemid 29266983)
44. Vedder H, Anthes N, Stumm G, Wurz C, Behl C, Krieg JC. Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J Neurochem 1999; 72: 2531-2538. (Pubitemid 29242205)
45. Rosler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl 1998; 54: 211-219. (Pubitemid 28539358)
46. Pitchumoni SS, Doraiswamy PM. Current status of antioxidant therapy for Alzheimer's Disease. J Am Geriatr Soc 1998; 46: 1566-1572. (Pubitemid 28551206)
47. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997; 22 (1-2): 359-378.
48. Muller U, Krieglstein JP. Prolonged pretreatment with alphalipoic acid protects cultured neurons against hypoxic, glutamate-, or iron-induced injury. J Cereb Blood Flow Metab 1995; 15: 624-630.
49. Mazzini L, Testa D, Balzarini C, Mora G. An open randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 1994; 241: 223-227. (Pubitemid 24072934)
50. Jossan SS, Ekblom J, Gudjonsson J, Hagbarth KE, Aquilonius SM. Double blind crossover trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm 1994; 41: 237-241. (Pubitemid 24215696)
51. Lange DJ, Murphy PL, Diamond B, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998; 55: 93-96. (Pubitemid 28139110)
52. Wiedau-Pazos M, Goto JJ, Rabizadeh S. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996; 271: 515-518. (Pubitemid 26044472)
53. Hottinger AF, Fine EG, Gurney ME, Zum AD, Aebischer P. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. European J Neurosci 1997; 9: 1548-1551. (Pubitemid 27303257)
54. Vyth A, Timmer JG, Bossuyt PM, Louwerse ES, deJong JM. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci 1996; 139 (Suppl): 99-103.
55. Conradi S, Ronnevi L-O, Nise G, Vesterberg O. Long-time penicillamine treatment in Amyotrophic Lateral Sclerosis with parallel determination of lead in blood, plasma and urine. Acta Neurol Scandinav 1982; 65: 203-211. (Pubitemid 12185291)
56. Bousser MG, Malier M. Penicillamine in amyotrophic lateral sclerosis. Lancet 1979; i: 168. (Pubitemid 9104483)
57. Justic A, Sostarko M. Improvement of spinal amyotrophy by penicillamine therapy. Lancet 1977; ii: 1034-1035. (Pubitemid 8215414)
58. House AO, Abbott RJ, Davidson DL. Response to penicillamine of lead concentrations in CSF and blood in patients with motor neuron disease. Br Med J 1978; ii: 1684. (Pubitemid 9093549)
59. Apostolski S, Marinkovicz Z, Nikolic A, Blagojevic D, Spasic MB, Michelson AB. Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. J Environm Pathol Toxicol Oncol 1998; 17 (3-4): 325-329. (Pubitemid 28380881)
60. Stevic Z, Nikolic A, Blagojevic D, et al. A controlled trial of combination of methionine and antioxidants in amyotrophic lateral sclerosis. Proc ALS/MND International Alliance Meeting, Munich, Germany 1998; [Abstract].
61. Mitsumoto H, Chad DA, Pioro EP. Excitotoxicity and oxidative damage in ALS pathogenesis. In: Amyotrophic Lateral Sclerosis. Philadelphia, PA: Oxford University Press; 1998: 197-225.
62. Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol 1996; 6: 679-687. (Pubitemid 26387725)
63. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196-203. (Pubitemid 27283649)
64. Eisen A, Weber M. Treatment of amyotrophic lateral sclerosis. Drugs Aging 1999; 14: 173-196. (Pubitemid 29123600)
65. Banerjee KK, Marimuthu P, Sarkar A, Chaudhuri RN. Influence of cigarette smoking on vitamin C, glutathione and lipid peroxidation status. Indian J Public Health 1998; 42: 20-23. (Pubitemid 128146705)
66. Nakamura K, Stadtman ER. Oxidative inactivation of glutamine synthetase subunits. Proc Natl Acad Sci USA 1984; 81: 2011-2015.